# PTC Therapeutics, Inc. (PTCT) · Edgar & Edgarette company card

> PTC Therapeutics, Inc. (PTCT) grew revenue 115% in FY2025 to $1.7 billion, operating margin 50.1% against a -3.8% median for pharmaceutical preparations, equity -7.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1070081 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/PTCT) · [JSON](https://www.pops4.com/boards/company/PTCT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $1.7B |
| Revenue growth, 1 year | 114.5% |
| Revenue growth per year | 33.9% |
| Operating margin | 50.1% (prior year -37.5%) |
| Net margin | 39.4% |
| Operating cash flow | $711M |
| Capital spending | $9M |
| Free cash flow | $702M |
| Cash | $985M |
| Long-term debt | — |
| Total assets | $2.9B |
| Total equity | −$205M |
| Equity ÷ assets | -7.1% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 1.56 (grey zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); revenue is hard to predict: its 80% range is ±39%
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $1.7B (FY2025). Experience: revenue up 114.5% on the year, up 33.9% a year over 4 years; operating margin 50.1%, up from -37.5%. Soundness: equity -7.1% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $2.0B and $4.5B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $1.5B to $6.0B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 50.1% against a -3.8% median; growth 114.5% against 13.7%.

Range logged 2026-09-27, receipt 997e8361e3927d94, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-07-30 ([filing](https://www.sec.gov/Archives/edgar/data/1070081/000107008126000016/0001070081-26-000016-index.htm))

## Recent filings

- 8-K · filed 2026-11-03 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1070081/000110465926121713/0001104659-26-121713-index.htm)
- 10-Q · filed 2026-10-29 · [filing](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120223/0001104659-26-120223-index.htm)
- 8-K · filed 2026-10-29 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120200/0001104659-26-120200-index.htm)
- 8-K · filed 2026-09-21 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1070081/000107008126000023/0001070081-26-000023-index.htm)
- 8-K · filed 2026-08-28 · 1.01 Entry into a Material Definitive Agreement · [filing](https://www.sec.gov/Archives/edgar/data/1070081/000107008126000019/0001070081-26-000019-index.htm)
- 8-K · filed 2026-08-13 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1070081/000110465926095424/0001104659-26-095424-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001070081.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1070081

## Cite

POPS4, Edgar & Edgarette: PTC Therapeutics, Inc. (PTCT) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/PTCT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.